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ABSTRACT 
International Journal of Exercise Science 11(3): 669-680, 2018. Habitual endurance training may be 
associated with mild airway inflammation and subsequent deterioration in lung function. PCSO-524™ 
(Lyprinol®/Omega-XL®), a supplement extracted from the New Zealand green-lipped mussel (Perna canaliculus), 
has been shown to moderate airway inflammation in asthmatic subjects. The purpose of this study was to determine 
whether supplementation with PCSO-524™ improves pulmonary and respiratory muscle function in non-
asthmatic elite runners. Sixteen male, non-asthmatic elite runners were randomly assigned to either a treatment 
(PCSO-524™; 1 capsule contains 50 mg n-3 polyunsaturated fatty acids and 100 mg olive oil, n=8) or placebo (1 
capsule contains 150 mg olive oil; n=8) group.  During the supplementation period, subjects ingested 8 capsules of 
either treatment or placebo per day for 12 weeks.  Resting pulmonary and respiratory muscle function testing were 
assessed at baseline and every two weeks throughout the 12 week supplementation period. No significant between- 
or within-subjects main effects were observed in forced vital capacity, forced expiratory volume in 1-second, forced 
expiratory flow from 25-75% of lung volume (FEF25-75), peak expiratory flow, maximal voluntary ventilation, 
maximal inspiratory mouth pressure, and closing volume (p>0.05).  A significant within-subjects main effect was 
observed in maximal expiratory mouth pressure (PEmax) (p=0.024) and lung diffusion capacity (DLCO) (p<0.0001), 
but no significant between-subjects main effects were observed for PEmax and DLCO (p>0.05).  A significant treatment 
by time interaction was observed in FEF25-75 (p=0.026) and DLCO (p=0.024), but no other significant interactions were 
observed (all p>0.05). Supplementation with PCSO-524™ (Lyprinol®/Omega-XL®) does not improve pulmonary 
or respiratory muscle function in non-asthmatic elite runners. 
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Regular training of endurance athletes in cold or temperate environments is associated with 
mild airway inflammation (5, 6, 13, 24, 32). Airway inflammation, coupled with acute 
immunosuppression during periods of high training volume, may put athletes at risk for upper 
respiratory tract infection and related performance decrements (4, 7, 11, 26). The precise 
mechanism behind this airway inflammation is unclear (31). While it may not be due to 
bronchial hyper-reactivity, post-exercise respiratory symptoms (5, 13), or immune cell activation 
(5, 6, 24), it may be associated with elevated airway neutrophil counts (5, 6, 8, 24), as well as 
insufficient conditioning of inspired air and osmotic changes that damage the epithelium (3). 
Mitigating airway inflammation has been shown to improve exercise tolerance in asthmatic 
populations (12); therefore, endurance athletes may benefit from interventions that can modify 
the severity of airway inflammation.  
 
Current evidence suggests that the incorporation of supplements such as fish oil that contain n-
3 polyunsaturated fatty acids may be beneficial in modifying the severity of airway 
inflammation patients with asthma (16-18).  Fish oils containing high levels of the n-3 
polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have 
been shown to have a protective effect on airway function in elite athletes (20) and asthmatics 
(19), and may have an ergogenic effect on exercise performance (30).  We have recently shown 
that PCSO-524™ (Lyprinol®/Omega-XL®), which is a patented marine oil extract of stabilized 
lipids from the New Zealand green-lipped mussel, Perna canaliculus, combined with olive oil 
and vitamin E (10), can attenuate airway inflammation and the severity of exercise-induced 
bronchoconstriction (EIB) in asthmatics (22) and reduce exercise-induced muscle damage and 
delayed-onset muscle soreness (21). This is likely through the action of furan fatty acids (34) and 
inhibition of the cyclooxygenase-2 and 5-lipoxygenase pathways, resulting in a significant 
reduction in pro-inflammatory prostanoids and leukotrienes, and a subsequent reduction in 
cytokine production from inflammatory cells (21, 35). Despite these potential benefits, the utility 
of such a nutritional approach has not been examined in non-asthmatic athletes.  
 
PCSO-524™ is a mixture of the five main lipid classes including sterol esters, triglycerides, free 
fatty acids, sterols, and polar lipids (36), and has been shown to contain up to 91 fatty acids, with 
docosahexanoic acid (DHA) and eicosapentanoic acid (EPA) accounting for 84% of the n-3 
polyunsaturated fatty acid content (36).  PCSO-524™ has been shown to exert potent anti-
inflammatory effects through the action of furan fatty acids (34) and inhibition of the 
cyclooxygenase-2 and 5-lipoxygenase pathways, which normally metabolize arachidonic acid 
into pro-inflammatory prostanoids and leukotrienes (21, 35).  The inhibitory effects of PCSO-
524™ on these pathways therefore produce a significant reduction in pro-inflammatory 
prostanoids and leukotrienes, and a subsequent reduction in cytokine production from 
inflammatory cells. 
 
Therefore, the purpose of this study was to evaluate the effects of PCSO-524™ supplementation 
on pulmonary and respiratory muscle function in non-asthmatic elite runners.  Given that 
runners who undertake a period of high training volume may be susceptible to mild airway 
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inflammation, we hypothesized that PCSO-524™ supplementation would improve pulmonary 





Sixteen elite non-asthmatic male runners participated in the study.  One additional participant 
enrolled in the study but dropped out due to reasons unrelated to the study (subject relocated 
to a different city and was no longer able to participate).  Participant information is given in 
Table 1.  In order to be enrolled in the study, subjects were required to be classified as “elite” 
(which we defined as a personal best competition time of < 15 min for 5 km or < 30 min for 10 
km race, or equivalent for other running events) and be rated as low risk based on American 
College of Sports Medicine risk stratification criteria (15).  Subjects were excluded if they had 
any history of pulmonary or cardiovascular disease, or allergies to fish, seafood, or shellfish, as 
assessed by questionnaire. All subjects entered the study on their normal diet and training 
regimen and were told to maintain both throughout the study period.  Prior to each testing 
session, subjects were instructed to refrain from strenuous exercise and from consuming caffeine 
and alcohol for 6 hours prior to each testing session. All testing procedures and the informed 
consent statement were approved by the Indiana University Human Subjects Committee and 
conformed to the guidelines set out in the Declaration of Helsinki.  Written informed consent 
was obtained before participants were enrolled in the study.  Sample size was based on an a 
priori power analysis (G*Power 3.1.3, Franz Faul, Germany) of each dependent measure (22) at 
a power of 0.8 (d = 0.6).  However, we acknowledge that the expected effect size in this healthy, 
highly-trained subject population could be expected to be smaller compared to the asthmatic 
subjects in the above-referenced study (22). 
 
Table 1. Participant information.  Data are presented as mean ± SE. 
Variable Mean ± SE 
Age (y) 23.9 ± 0.6 
Stature (cm) 179.6 ± 1.3 
Body Mass (kg) 68.1 ± 1.1 
Training History (months) 124.0 ± 10.6 
5000m run Personal Best (s) 884.0 ± 8.9 
 
Protocol 
The study was conducted as a randomized, placebo-controlled, parallel group study over 12 
weeks.  Subjects visited the laboratory a total of 7 times, at baseline, and every two weeks 
thereafter throughout the study period.  Following baseline testing, subjects were randomly 
assigned to either the treatment (PCSO-524™, Lyprinol®/Omega-XL®; n = 8) or placebo (olive 
oil; n = 8) group.  Supplementation information is given below.  Group assignment was double-
blinded, randomized, and counterbalanced (by resting pulmonary and respiratory muscle 
function).  Both groups were instructed to consume 8 of their assigned capsules per day, every 
day throughout the 12-week study period.  Subjects were instructed to return any unconsumed 
pills every two weeks and compliance for all subjects was assessed by counting the unconsumed 
pills for each subjects and dividing by the prescribed number of pills.  Figure 1 illustrates the 
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study timeline.  Pulmonary and respiratory muscle function were measured during each visit 
(every 2 weeks). 
 
 
Figure 1.  Study timeline.  Pulmonary and respiratory muscle function was measured during each visit.  Subjects 
were instructed to ingest 8 capsules of either placebo (olive oil) or PCSO-524™ per day throughout the 12 week 
supplementation period. 
 
Supplementation: During the supplementation period, subjects ingested 8 capsules per day of 
the assigned supplement (PCSO-524™ or placebo) for 12 weeks.  The treatment group (n = 8) 
received PCSO-524™ (Lyprinol®/Omega-XL®; Pharmalink International Ltd, Hong Kong), 
which contained 50 mg lipid extract (fatty acids), 7.3 mg (14% EPA), 5.5 mg (11% DHA), 100 mg 
olive oil, and 0.225 mg vitamin E (d-alpha tocopherol) per capsule.  The prescribed 
supplementation equaled 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA), 
and 1.8 mg vitamin E (d-alpha-tocopherol) per day for the treatment (PCSO-524™) group.  The 
placebo group (n = 8) received capsules containing 150 mg olive oil per capsule.  The prescribed 
supplementation equaled 1200 mg olive oil per day for the placebo group.  The active capsules 
(PCSO-524™) were identical in size, color, texture, and taste to the placebo counterpart.  The 
trial sponsor (Pharmalink) provided product specifications to the investigators.  Analysis of the 
raw materials was conducted by an independent laboratory (Cawthron Laboratories, Nelson, 
NZ) and analysis of the final, finished PCSO-524™ product was conducted by a separate, 
independent laboratory (Chemisches Labor, Hannover, Germany).  Placebo capsules were 
analyzed by Alpha laboratories (Auckland, NZ).  Specific active product (PCSO-524™; Batch 
No. A6530-01) and placebo (Batch No. 7820) information is presented in Table 2.  A full 
description of the composition of PCSO-524™ can be found elsewhere (21, 36). 
 
Int J Exerc Sci 11(3): 669-680, 2018 
International Journal of Exercise Science      http://www.intjexersci.com  
 673 
 
Table 2. Fatty acid composition (%) of PCSO-524™, a patented marine oil extract of the New Zealand green-
lipped mussel (Perna canaliculus)* and placebo (olive oil)** capsules.   
Lipid Name Common Name PCSO-524™ (Weight, %) Placebo (olive oil) (Weight, %) 
14:0 Myristic acid 1.7  
16:0 Palmitic acid 13.4 9.2 
16:1 Palmitoleic acid 3.6 3.0 
18:0 Stearic acid 3.6 3.5 
18:1 Oleic acid 58.2 81.0 
18:2n-6 Linoleic aced 5.7 2.6 
18:3n-3 Alpha-linolenic acid 0.9 0.4 
18:4n-3 Octadecatetraenoic acid 1.0  
20:0 Arachidic acid 0.4 0.3 
20:1 Eicosamonoenoic acid 0.7  
20:4n-6 Arachidonic acid 0.1  
20:4n-3 Eicosatetraenoic acid 0.3  
20:5n-3 Eicosapentaenoic acid 5.8  
22:5n-3 Docosapentaenoic acid 0.3  
22:6n-3 Docosaphexaenoic acid 3.0  
Others   1.3   
*Batch number: A6530-01; **Batch number: 7820.  Lipid name given as: carbon chain length:number of double 
bonds, position of last double bond from methyl (omega) end 
 
Pulmonary Function Testing: During each testing session, subjects completed pulmonary 
function (dynamic lung volumes, diffusing capacity of the lung, and closing volume) testing 
according to American Thoracic Society guidelines (1) as previously described in our laboratory 
(29). All pulmonary function testing was conducted with a calibrated metabolic cart (Vmax 
Encore system, CareFusion, Yorba Linda, CA, USA).  In addition to these spirometry tests, 
subjects completed three maximal flow-volume maneuvers, which were initiated from residual 
lung volume (RV) after several resting tidal breaths.  From RV, subjects were instructed to 
inspire as quickly and forcefully as possible to total lung capacity (TLC), and then expire as 
quickly and forcefully as possible back to RV. Forced vital capacity (FVC), forced expiratory 
volume in 1 s (FEV1.0), peak expiratory flow (PEF), and forced expiratory flow from 25-75% of 
lung volume (FEF25-75) were calculated from each maneuver.  If either FVC or FEV1.0 values 
varied by more than 0.15 L, additional trials were completed until three reproducible trials were 
achieved. 
 
Pulmonary diffusing capacity of the lung (DLCO) was assessed in duplicate using the single-
breath method (25, 28) with a 5 minute washout period between measurements. Closing volume 
(CV) was assessed by a single-breath O2 method as previously described (23, 27). CV measures 
were performed in duplicate with a 10 minute washout period between measurements. 
 
Respiratory Muscle Function Testing: Respiratory muscle function testing (maximal 
inspiratory/expiratory mouth pressures and maximal voluntary ventilation) was completed 
during each testing session in a seated, upright position using the same calibrated metabolic cart 
according to published guidelines (ATS/ERS 2002).  Maximal voluntary ventilation in 12-
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seconds (MVV) was measured as an index of respiratory muscle endurance.  Briefly, subjects 
were instructed to inspire and expire the highest volume of air possible during a 12-second time 
period following a period of normal tidal breathing.  Breathing frequency and tidal volume were 
self-selected by subjects during the MVV test.  Respiratory muscle strength was assessed by 
maximal inspiratory and expiratory mouth pressures (PImax and PEmax, respectively).  PImax and 
PEmax tests were initiated from RV and TLC, respectively, then subjects were instructed it 
inspire/expire as forcefully as possible while the opening of the mouthpiece was occluded.  The 
maneuver was sustained for a minimum of 1 s according to published guidelines (2).  Subjects 
repeated the maneuvers until three trials within 10% of each other were observed.  The highest 
values are reported. 
 
Statistical Analysis 
Data for all participants (n = 16) were analyzed using SAS 9.4 (SAS Institute, Cary, NC, USA) 
statistical software.  Pulmonary and respiratory muscle function measures were compared 
between groups using a two-way (treatment x time), repeated-measures analysis of variance 
(ANOVA).  Normality of data was assessed using the Shapiro-Wilk test.  Sphericity of data was 
assessed using Mauchly’s sphericity test.  When sphericity was violated, the departure from 
sphericity (ε) was calculated.  If ε was < 0.75, the Huynh-Feldt correction factor was applied and 
if ε was > 0.75, the Greenhouse-Geisser correction factor was applied.  Where significant main 
effects were observed, post-hoc comparisons were made using Tukey’s test.  Statistical 




No significant between-subjects main effects were observed in pulmonary function (FVC, 
FEV1.0, FEF25-75, PEF, DLCO, and CV) or respiratory muscle function (MVV, PImax, and PEmax) (all 
p > 0.05).  A significant within-subjects main effect was observed in PEmax (p = 0.024) and DLCO 
(p < 0.0001).  No significant within-subject main effects were observed in FVC, FEV1.0, FEF25-75, 
PEF, MVV, PImax, and CV (all p > 0.05).  A significant treatment by time interaction was observed 
in FEF25-75 (p = 0.026) and DLCO (p = 0.024), but no other significant interactions were observed 
(all p > 0.05).  Spirometry data are presented in Figure 2; respiratory muscle function, CV, and 




The main finding of this study was that supplementing with a marine oil lipid and n-3 PUFA 
blend did not improve resting pulmonary and respiratory muscle function in non-asthmatic elite 
runners compared to placebo.  No differences were observed between groups in any pulmonary 
or respiratory muscle function measures, however a significant treatment by time interaction 
was observed in FEF25-75 and DLCO.  Therefore, non-asthmatic elite runners are unlikely to 
experience benefits in pulmonary and respiratory muscle function from supplementation with 
this marine oil extract during periods of heavy training. 
 
Table 3. Respiratory muscle function, CV, and DLCO data.  TRT, treatment (PCSO-524™) group; PLA, placebo 
group; MVV, maximal voluntary ventilation (L·min-1); PImax, maximal inspiratory mouth pressure (cmH2O); PEmax, 
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maximal expiratory mouth pressure (cmH2O); CV, closing volume (% of forced vital capacity); DLCO, pulmonary 
diffusion capacity (mL CO·min-1·mmHg-1).  Data are presented as mean ± SE. 
    Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 
    PCSO-524™ Treatment 
MVV Mean 192.9 203.5 195.1 195 209.8 204.5 207.8 
(L·min-1) (SE) (7.6) (13.7) (12.3) (9.5) (9.9) (10.9) (10.8) 
PImax  Mean 127.3 124.8 126.1 126.4 124.8 123.6 122.8 
(cmH2O) (SE) (9.0) (9.6) (11.5) (10.9) (10.5) (10.8) (9.0) 
PEmax  Mean 148.0 142.3 145.4 150.5 146.0 156.6 158.4 
(cmH2O) (SE) (7.8) (5.4) (6.9) (5.5) (9.3) (9.3) (9.6) 
CV Mean 10.5 8.9 9.9 10.1 10.0 9.6 9.6 
 (% FVC) (SE) (0.4) (0.3) (0.6) (0.4) (0.4) (0.3) (0.5) 
DLCO  Mean 38.8 40.6 39.4 38.8 38.5 37.5 36.6 
(mL CO·min-1 ·mmHg-1) (SE) (1.3) (1.6) (1.8) (1.7) (1.6) (1.5) (1.5) 
    Placebo 
MVV Mean 194.1 191.4 191.6 185.1 191.6 185.3 190.6 
(L·min-1) (SE) (6.1) (6.6) (7.5) (6.2) (8.8) (5.4) (5.4) 
PImax  Mean 135.8 135.3 135.5 136.5 136.1 138.5 142.6 
(cmH2O) (SE) (14.8) (12.5) (12.6) (12.6) (12.2) (11.8) (12.1) 
PEmax  Mean 158.6 156.6 159.8 163.8 173.6 173.0 172.6 
(cmH2O) (SE) (15.7) (15.7) (12.6) (10.2) (11.0) (11.4) (12.4) 
CV Mean 10.5 9.5 9.0 9.0 9.5 9.6 9.8 
 (% FVC) (SE) (0.6) (0.5) (0.4) (0.6) (0.4) (0.5) (0.5) 
DLCO  Mean 40.9 39.3 39.1 38.5 39.5 34.7 35.7 
(mL CO·min-1 ·mmHg-1) (SE) (1.7) (1.1) (1.3) (1.3) (1.4) (1.2) (1.2) 
 
Our significant finding included a treatment by time interaction was observed in DLCO (p = 0.024) 
and FEF25-75 (p = 0.026), indicating the athletes decreased expiratory flow as well as diffusing 
capacity. A possible reason for decreased DLCO could be pulmonary edema due to airway 
inflammation during a period of high training volume, as seen acutely following an endurance 
exercise bout (14, 23). This could occur as a negative result of high volume training, despite 
increased membrane diffusing capacity and thus higher DLCO found in trained populations 
versus controls (33). Possible reasons for decrease in FEF25-75 in the treatment group could be 
due to small airway obstruction or bronchoconstriction, although unlikely because our athletes 
were non-asthmatic. However, the increase in FEF25-75 observed in the placebo group is 
unexpected.  It is unlikely to be a result of familiarity or a learning effect given that subjects 
completed the tests multiple times and were familiarized with the procedure.  It is possible that 
external factors which modify airway caliber, such as training load or environmental exposures, 
could have influenced the flow rates produced by these subjects.  However, these claims are 
merely speculative, as our data cannot give mechanistic insight into these hypotheses. 
Int J Exerc Sci 11(3): 669-680, 2018 




Figure 2. Spirometry data for both 
treatment (closed circles/triangles) and 
placebo (open circles/triangles) groups.  No 
significant between-subject effects were 
observed (all p > 0.05).  PEF, peak expiratry 
flow (L·s-1); FEF25-75, forced expiratory flow 
from 25-75% of lung volume (L·s-1); FVC, 
forced vital capacity (L); FEV1.0, forced 
expiratory volume in 1 s (L).  *A significant 
treatment by time interaction was observed 
in FEF25-75 (p = 0.026). 
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Although this supplementation protocol did not improve resting lung function in elite athletes, 
it is unclear whether marine oil extract could improve the acute impairments in lung function 
that are found to occur after exercise.  Even though elite athletes often have above-average 
resting lung function, the occurrence of a transient post-exercise narrowing of the airways, 
termed exercise-induced bronchoconstriction (EIB), is common after training or competition (4).  
Respiratory variables such as FVC, FEV1, and DLCO may be reduced, and variables such as RV 
and CV may be increased, after sustained running exercise, possibly due to perivascular or 
peribronchial edema or changes in pulmonary capillary blood flow (14, 23).  We have shown 
that supplementation with marine oil extract mitigates these symptoms in asthmatics (22). We 
therefore propose that future investigations elucidate whether supplementation with this 
marine oil extract has a protective effect on lung function immediately post-exercise in non-
asthmatic elite runners. 
 
In addition to resting or post-exercise lung function, this supplement has been used to reduce 
markers of airway inflammation (cysteinyl leukotrienes, 11β-prostaglandin, Club cell proteins) 
in asthmatic populations (22).  Similar airway inflammation may also be present during habitual 
endurance training in non-asthmatic athletes; however, it remains unclear whether this occurs 
consistently in elite runners.  While acute exercise may induce short-term immune dysfunction, 
and intensified training may compromise immune function over a longer term, this does not 
represent clinical immunodeficiency in elite athletes (11).  As such, Chimenti et al., (8, 9) 
demonstrated that neutrophil counts increased after running races, but did not find evidence of 
chronic airway inflammation in a longitudinal field study in healthy runners.  Further, chronic 
endurance training has been shown to induce potent anti-inflammatory effects mediated 
through cytokines in tandem with downregulation of toll-like receptor expression (11).  Thus, it 
is likely that the athletes in the present study had a high capacity to mitigate airway 
inflammation induced by running exercise and therefore did not experience any additional 
beneficial effects supplementing with the marine oil extract.  Additionally, it is possible that 
healthy runners are not significantly affected by exposure to mild seasonal changes and airborne 
pollutants that cause bronchial hyper-reactivity in asthmatic populations, and therefore may not 
experience significant airway inflammation even during sustained exercise.  We did not take 
any measures of inflammation or neutrophil counts, and therefore we are unable to confirm the 
presence or severity of airway inflammation in our subjects, and the subsequent effect of marine 
oil extract supplementation.  Moreover, the effects of mild seasonal changes and airborne 
pollutants were not assessed, thus these factors could have influenced our results.  Future 
studies should aim to confirm the presence and evaluate the severity of airway inflammation in 
elite runners during a period of intensified training, and the effect of marine oil extract 
supplementation on those symptoms and the resulting athletic performance.   
 
In summary, we have demonstrated that there did not appear to be any positive effect of 
supplementation with PCSO-524™, a marine oil lipid extract derived from the New Zealand 
green lipped mussel (Perna canaliculus), on resting pulmonary and respiratory muscle function 
in non-asthmatic elite runners.  Therefore, non-asthmatic elite runners aiming to optimize 
resting pulmonary function through nutraceutical supplementation are unlikely to obtain any 
benefits from using this marine oil extract. 
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